Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms | Zendy

Jennifer K. Rogers | Zendy; John J.V. McMurray | Zendy; Stuart J. Pocock | Zendy; Faı̈ez Zannad | Zendy; Henry Krum | Zendy; Dirk J. van Veldhuisen | Zendy; Karl Swedberg | Zendy; Harry Shi | Zendy; John Vincent | Zendy; Bertram Pitt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms

Author(s) -

Jennifer K. Rogers,

John J.V. McMurray,

Stuart J. Pocock,

Faı̈ez Zannad,

Henry Krum,

Dirk J. van Veldhuisen,

Karl Swedberg,

Harry Shi,

John Vincent,

Bertram Pitt

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.110536

Subject(s) - eplerenone , medicine , heart failure , cardiology , interquartile range , placebo , confidence interval , spironolactone , alternative medicine , pathology

Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients with heart failure and mild symptoms. In chronic diseases such as heart failure, characterized by repeat hospitalizations, analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research